Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.

Highlights: [•] CAF09 is a novel cationic liposomal adjuvant formulation comprising Poly(I:C). [•] CAF09 induces cross-priming and CD8+ T cells against protein/peptide antigens. [•] CAF09 induces cytotoxic CD8+ T-cell responses. [•] Immunization route is important for maximal CD8+ T-cell responses. [•] HPV-E7 formulated in CAF09 confers protection in a TC-1 skin tumor model. [Copyright &y& Elsevier]